JOURNAL OF CLINICAL SURGERY ›› 2025, Vol. 33 ›› Issue (10): 1048-1052.doi: 10.3969/j.issn.1005-6483.20250983

Previous Articles     Next Articles

The current situation and challenges of liver resection for hepatocellular cancinoma

YANG Xin,XU Da,QIN Lunxiu   

  1. Hepatobiliary Surgery Center, Department of General Surgery, Huashan Hospital Fudan University,Shanghai 200040, China
  • Received:2025-10-15 Online:2025-11-11 Published:2025-11-11

Abstract: Surgical resection remains the primary option for achieving radical cure and long-term survival in the treatment of liver cancer.In recent years,profound changes have taken place in the field of liver surgery:the surgical concept of liver resection for liver cancer has been constantly updated;Significant progress has also been made in many aspects such as liver imaging technology,liver resection techniques and equipment,and perioperative management.Liver resection for liver cancer has gradually developed into a more precise,minimally invasive and safer treatment model.However,liver resection for liver cancer still faces many new challenges up to now:the prevention strategies for recurrence and metastasis are limited;There is a lack of predictive indicators for the efficacy of targeted immunotherapy.Insufficient precision in individualized treatment,etc.

Key words: hepatocellular carcinoma, hepatectomy, surgical concept, surgical techniques

[1] . Relationship of the Cyclin B2 and Cyclin E1 expression with clinicopathological characteristics and 5-year survival rate of patients with hepatocellular carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(9): 981-984.
[2] PAN Junhao, WANG Chunhui. Constructing a prognostic prediction model for distant metastatic hepatocellular carcinoma based upon SEER data [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(4): 410-415.
[3] Chinese Chapter of the International Hepato-Pancreato-Biliary Association, Hepatic Surgery Group of Surgical Branch of Chinese Medical Association. Expert consensus on safety assessment of hepatectomy for hepatocellular carcinoma with HBV-related liver cirrhosis [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(3): 225-236.
[4] WANG Hao,Liang Binyong,MEI Bin. Progress in neoadjuvant therapy for hepatocellular carcinoma based on immune checkpoint inhibitors [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(3): 332-335.
[5] The Chinese Chapter of the International Hepato-Pancreato-Biliary Association, Group of Liver Surgery, Surgical Society of Chinese Medical Association, Enhanced Recovery of Oncology Surgery Professional Committee, Chinese Anti-Cancer Association. Guidelines for multidisciplinary clinical management of perioperative period of hepatectomy (2025 edition) [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(10): 1009-1038.
[6] TANG Haowen, CAO Yinbiao, LU Shichun. Novel strategies for the management of hepatocellular carcinoma with portal vein tumor thrombus [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(10): 1053-1057.
[7] ZHAN Xuezhi, YU Jin, ZHU Yuan, LIAO Xiaofeng, LI Xiaogang. The influence of preoperative transarterial chemoembolizationon the early recurrence of stage Ⅰb-Ⅱa diagnosed liver cancer [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(10): 1073-1076.
[8] WANG Mingquan,WANG Huizhe,LU Shuangdong,WANG Qian,CAI Zengqiang. The predictive value of serum uric acid levels for the occurrence of sarcopenia after hepatectomy in patients with primary liver cancer [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(9): 937-941.
[9] YIN Qiang, HU Yongjun, WANG Lei, YAN Huajun, SHEN Xiongshan. Application experience of three dimensional reconstruction technique in laparoscopic hepatectomy for hepatic carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(5): 499-501.
[10] HUANG Hongwei,CHEN Qi,LIAO Wei,ZHANG Kaiyue,WANG Hao,MEI Bin. Postoperative adjuvant immunotherapy for huge hepatocellular carcinoma in China liver cancer staging Ⅲa [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(4): 386-390.
[11] ZENG Yingying,ZHU Yuhao,WANG Yongfei,LEI Shizhou,JIANG Bin. Application of Glisson pedicle approach based on anterrior pedicle-posterior pedicle-right hepatic triangle in laparoscopic anatomic right anterior lobectomy [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(3): 285-288.
[12] ZHOU Yi,LIANG Binyong,XIAO Zhenyu. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(3): 328-331.
[13] XIONG Jianwei, LI Qiang, TANG Tao, ZHANG Lixin, YING Bao, ZHAO Kaifeng, XIONG Yongfu, LI Jingdong, WU Guo. Efficacy and safety of transhepatic arterial chemoembolization combined with tyrosine kinase inhibitor and programmed death receptor-1 inhibitors in the treatment of  intermediate and a-dvanced unresectable hepatocellular carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(2): 176-181.
[14] XIE Zhenhui,HUANG Zhiyong. Effect of Pringle maneuver on prognosis of patients with hepatocellular carcinoma during hepatectomy [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(12): 1340-1342.
[15] MU Xixi, LI Jing, ZHANG Xuan, et al. Expression levels and clinical diagnostic value of miR-3619-5p and LINC00857 in serum of hepatocellular carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(6): 572-575.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!